



Centers for Disease Control  
and Prevention (CDC)  
Atlanta GA 30333

April 12, 2023

Aaron Siri  
Siri & Glimstad, LLP  
745 Fifth Ave.  
Suite 500  
New York, NY 10151  
Via email: foia@sirillp.com

Dear Mr. Siri:

This letter is our final response to your Centers for Disease Control and Prevention and Agency for Toxic Substances and Disease Registry (CDC/ATSDR) Freedom of Information Act (FOIA) request of March 17, 2023, assigned #23-00898-FOIA, for (see attached request).

The records used to support the safety of vaccine coadministration referenced in the tweet are:

From the publicly available White House video: [https://files.hiv.gov/s3fs-public/2022-12/HHS\\_OIDP\\_MonkeypoxFAQs\\_DemetreDaskalakis\\_Q13.mp4](https://files.hiv.gov/s3fs-public/2022-12/HHS_OIDP_MonkeypoxFAQs_DemetreDaskalakis_Q13.mp4)

From CDCs publicly available website: JYNNEOS Vaccine website  
<https://www.cdc.gov/poxvirus/mpox/interim-considerations/jynneos-vaccine.html#coadministration>

Currently, there are no data on administering JYNNEOS vaccine at the same time as other vaccines. Because JYNNEOS is based on a live, attenuated non-replicating orthopoxvirus, JYNNEOS typically may be administered without regard to timing of most other vaccines. This includes simultaneous administration of JYNNEOS and other vaccines, including influenza vaccine, on the same day, but at different anatomic sites if possible. There are special considerations if administering the COVID-19 vaccine. See the Interim Clinical Considerations for Use of COVID-19 Vaccines (<https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html>), and best practices for multiple injections (<https://www.cdc.gov/vaccines/hcp/admin/administer-vaccines.html>).

Overall, the information above was developed based upon recommendations from the Advisory Committee on Immunization Practices (ACIP). Specifically:

- a. ACIP Smallpox and Monkeypox Vaccine Recommendations (<https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/smallpox.html>)
- b. ACIP Timing and Spacing Guidelines for Immunization (<https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/timing.html>)


Additionally, a June 2022 MMWR describes ACIP recommendations "Use of JYNNEOS (Smallpox and Monkeypox Vaccine, Live, Nonreplicating) for Preexposure Vaccination of Persons at Risk for Occupational Exposure to Orthopoxviruses: Recommendations of the Advisory Committee on Immunization Practices — United States, 2022" (<https://www.cdc.gov/mmwr/volumes/71/wr/mm7122e1.htm>)

Of note, the MMWR above states:

"Additional data on JYNNEOS vaccine are needed. Further studies are needed to determine the duration of protection after the 2-dose JYNNEOS vaccination series; recommendations regarding the frequency of booster doses can be modified accordingly. The effectiveness of a single dose JYNNEOS series should be evaluated if orthopoxvirus exposures occur before peak immunogenicity is achieved. Clinical trials evaluating the risk for myopericarditis and serious adverse events are needed to ensure that the risks are characterized and guidance about co-administration of JYNNEOS with mRNA COVID-19 vaccines can be elucidated."

If you need any further assistance or would like to discuss any aspect of the records provided please contact either our FOIA Requester Service Center at 770-488-6399 or our FOIA Public Liaison at 770-488-6246.

Sincerely,

A handwritten signature in black ink, appearing to read 'Roger Andoh', written in a cursive style.

Roger Andoh  
CDC/ATSDR FOIA Officer  
Office of the Chief Operating Officer  
(770) 488-6399  
Fax: (404) 235-1852

23-00898-FOIA